About
MasterSwitch Bio develops a modified mRNA therapy targeting Hepatocyte Nuclear Factor-4 alpha (HNF4α) to treat End Stage Liver Disease with cirrhosis by restoring hepatic function through upregulation of key hepatocyte proteins.
Explore MasterSwitch Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.